Company intelligence / Profile preview

Pacific GeneTech

Rogers, Arkansas, United States

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Pacific GeneTech develops next-generation recombinant and inactivated vaccines and adjuvants for animal health and food safety. Its first two Aegis poultry vaccines for Salmonella, Escherichia coli and coccidiosis have been out-licensed and are moving through USDA regulatory processes, while additional vaccines for swine, ruminants and human dysentery remain at proof-of-concept and pre-clinical stages.[1][4][8]

Therapeutic areas: Infectious Diseases
Modalities: VaccineBiologicDNA vaccineRecombinant protein
Industry: Veterinary

Partnerships

Kemin Biologics (exclusive agreement for Salmonella and Eimeria poultry vaccines)[8]Multiple commercial partners for out-licensed poultry vaccines (undisclosed)[4][8]Third-party vaccine makers licensing Hercules adjuvant (includes Kemin Biologics and others)[4][8]

Beyond the preview

Go deeper on Pacific GeneTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pacific GeneTech.

Explore the full profile